The FDA approved the first immunotherapy drug to treat breast cancer: Tecentriq.
Created by Swiss drugmaker, Roche, Tecentriq was approved on Friday for treating advanced triple-negative breast cancer. The drug will be used with chemotherapy and works by boosting the immune system’s ability to spot and kill cancer cells.
A whopping $13,400 per month.
Image Source: Tecentriq